Change of Certified Adviser (CA) to G&W Fondkommission

Regulatory

LIDDS AB (publ) hereby announces that the company has entered into an agreement with G&W Fondkommission regarding the role of Certified Adviser. G&W Fondkommission will assume the position of Certified Adviser as of 1 December.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

LIDDS’ Certified Adviser is G&W Fondkommission

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Change of Certified Adviser (CA) to G&W Fondkommission